Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › US phase 2 (NCT06124807)

US phase 2 (NCT06124807)

Mazdutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Mazdutide
Population
obesity
Phase
2
Participants
179
Duration
32 weeks
Registry
NCT06124807

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
3-6 mg (3 mg to week 32)obesity32179−7.3 % vs −0.9 %
Δ −6.4 pp
————————press release
10 mgobesity32179−15.6 % vs −0.9 %
Δ −14.7 pp
————————press release
16 mgobesity32179−18.1 % vs −0.9 %
Δ −17.2 pp
——20.0—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (4)
  • 3-6 mg (3 mg to week 32) · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 10 mg · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 16 mg · weight_eff · publication
    At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
  • 16 mg · ae_dc · publication
    discontinuation of study treatment due to adverse events occurred most frequently with 16 mg (20%)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: US phase 2 (NCT06124807). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06124807/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.